Blanket Purchase Agreement V797D70052-HHSI246201800069B

This Blanket Purchase Agreement (BPA) is a single-award federal contract Indefinite Delivery Vehicle (IDV) awarded by the Department of Veterans Affairs National Acquisition Center to Kaleo, Inc., a pharmaceutical company specializing in auto-injector technologies for life-saving medications. The BPA, valued at $5,025, is for the procurement of the opioid overdose reversal drug naloxone. As a manufacturer of critical medical countermeasures, Kaleo has established itself as a key supplier to...

The Blanket Purchase Agreement was awarded as a single award by the Department of Veterans Affairs National Acquisition Center to Aimmune Therapeutics, Inc. The potential value of the BPA is $14 million. The BPA is for the procurement of Palforzia, which is intended to reduce the frequency and severity of allergic reactions to peanuts in patients aged 4 through 17 years. No set-aside was used in the awarding of this BPA. The period of performance for orders placed against the BPA extends through...

This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Nephron Sterile Compounding Center LLC on March 1, 2020, with a potential value of $2.5 million. The BPA is for specialized compounded intravenous solutions with no set-aside used. The period of performance extends through the last date to order of September 30, 2023. The BPA facilitates recurring orders for specific pharmaceutical products and supplies, including Phenylephrine HCI Injection,...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Mayne Pharma Commercial LLC, doing business as Metrics Inc. The BPA is for the procurement of halobetasol and tazaroten pharmaceuticals under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The single-award BPA has a ceiling value of $5,216,518.00 and a period of performance through May 28, 2025. As a foreign-owned, for-profit manufacturer of goods, Mayne...

The Department of Veterans Affairs awarded a single-award indefinite delivery contract to DR Reddy's Laboratories, Inc. to supply an estimated 140,000 boxes annually of various strengths of Buprenorphine/Naloxone Film Sublingual. The contract has a one-year base period of performance beginning February 4, 2020 with four one-year option periods and a potential value of $42,763,747.32. The original solicitation sought to establish a prime vendor contract to supply Buprenorphine/Naloxone Film...

The government has awarded a Blanket Purchase Agreement (BPA) to Nephron Sterile Compounding Center LLC, a woman-owned limited liability company, to provide pharmaceutical products and supplies to the Defense Health Agency (DHA). The BPA has a ceiling value of $4,000,000 and a period of performance through March 31, 2025. Under this BPA, Nephron has received two specific task orders to date. The first is a $20,625 firm fixed price award for various injectable pharmaceutical products including...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Melinta Therapeutics, LLC. The BPA is established under the GSA Pharmaceutical and Drugs (FSS-61-IB) schedule and has a ceiling value of $500,000.00. The BPA is for the procurement of REZZAYO, with a period of performance through August 31, 2024. This single-award BPA aims to provide the agency a simplified method of filling repetitive needs for the specified pharmaceutical...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Civica Inc., a non-profit organization and manufacturer of goods. The BPA has a ceiling value of $625,000.00 and a period of performance ending on April 3, 2026. The BPA is for the procurement of the pharmaceutical products daptomycin, lorazepam, phenylephrine, and anectine. As a BPA, this contract vehicle allows the agency to place individual task orders for these products as needed...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Day One Biopharmaceuticals, Inc. The single-award BPA has a ceiling value of $15,000,000.00 and a period of performance ending on March 7, 2026. The BPA is for the procurement of OJEMDA, though the specific products and services to be delivered are not explicitly stated in the provided information. As a BPA, this contract vehicle allows the agency to place orders for recurring...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to HRA Pharma America, Inc. as the prime contractor. The BPA has a period of performance from June 10, 2025 to June 9, 2026 and a ceiling value of $1,386,062.00. The BPA is for the procurement of the pharmaceutical products Lysodren and Metopirone. No set-asides were used for this single-award contract. The purpose of this BPA is to establish a contract vehicle through which the...